Skip to content
Bored Studies
RecruitingPhase 2

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

Retension Pharmaceuticals. Inc. · NCT07142356

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
280
US sites recruiting
33
Study start
October 31, 2025
Record last updated
October 2, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this clinical trial is to measure the safety and efficacy of RTN-001 in adult participants with uncontrolled hypertension versus placebo.

Being studied: RTN-001; Matching placebo control

Conditions: Uncontrolled Hypertension

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Male or female patients age 18 to 75 years, inclusive, at the Screening Visit.
  • Uncontrolled HTN despite being on a stable regimen of 2-5 antihypertensive medications.
  • Mean BP of ≥135/80 mm Hg.
  • Body mass index of 18 to 35 kg/m2.

Exclusion Criteria

  • Mean seated SBP >175 mm Hg and/or DBP >110 mm Hg.
  • Current or planned use of nitrates and/or alpha-blockers or other drugs known to affect BP during the study period.
  • Participants who use PDE5 inhibitors for other indications that cannot or will not refrain from use of PDE5 inhibitors for 7 days before and during their entire period of participation in the study.
  • History of hypotension, fainting spells, blackouts or autonomic dysfunction, including orthostatic hypotension.
  • Known diagnosis of secondary hypertension (e.g. Cushing's Disease or hyperaldosteronism, renal fibrodysplasia, renal artery stenosis, etc., clinically significant aortic stenosis etc.).
  • Recent (within 3 months before the Screening Visit [Visit S1]) myocardial infarction; unstable angina leading to hospitalization; uncontrolled, symptomatic atrial fibrillation, or any cardiac arrhythmia that has not been clinically stable for at least 3 months prior to screening. Participants with implantable pacemakers or automatic implantable cardioverter defibrillators may be considered if deemed by the Investigator to be stable for the previous 3 months.
  • Uncontrolled hypothyroidism
  • Liver disease or dysfunction
  • Renal dysfunction (\<45 mL/min/1.73m²) or glomerulonephritis
  • Active infection or major illness
  • Gastrointestinal conditions or procedures (including weight loss surgery [eg, Lap-Band or gastric bypass]) that may affect drug absorption.
  • Hematologic or coagulation disorders
  • Active malignancy
  • Unexplained creatine kinase (CK) >3 × ULN at any time before randomization
  • A known history of temporary or permanent partial or total vision loss
  • A known history of "crowded" optic disc.
  • A known history of retinitis pigmentosa, a rare genetic eye disease.
  • Any prescription or over-the counter drugs or herbal supplements known to be strong inhibitors of CYP3A4 enzymes
  • NHYA class III-IV symptoms of heart failure.
  • History of diabetes or suspected diabetes with glycosylated hemoglobin > 10% or fasting glucose >250 mg/dl at Screening Visit (S1).

Recruiting US locations

  • Retension Clinical Site

    Alexander City, AL 35010

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Birmingham, AL 35222

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Tucson, AZ 85715

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    San Jose, CA 95128

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    West Hills, CA 91307

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Waterbury, CT 06708

    Site contact: CRO Call Center · participate@worldwide.com

  • CRO Call Center

    Maitland, FL 32751

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Orlando, FL 32801

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Port Orange, FL 32127

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Tampa, FL 33606

    Site contact: CRO Call Center · participate@worldwide.com

  • CRO Call Center

    Decatur, GA 30030

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Lawrenceville, GA 30044

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Peachtree Corners, GA 30092

    Site contact: CRO Call Center · participate@worldwide.com

  • CRO Call Center

    Indianapolis, IN 46202

    Site contact: CRO Call Center · participate@worldwide.com

  • CRO Call Center

    Munster, IN 46321

    Site contact: CRO Call Center · participate@worldwide.com

  • CRO Call Center

    New Orleans, LA 70115

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clincial Site

    Boston, MA 02131

    Site contact: CRO Call Center · participate@worldwide.com

  • CRO Call Center

    Methuen, MA 01844

    Site contact: CRO Call Center · participate@worldwide.com

  • CRO Call Center

    Overland, MO 66209

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Las Vegas, NV 89109

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Las Vegas, NV 89121

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    The Bronx, NY 10455

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Asheboro, NC 27203

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Charlotte, NC 28210

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Monroe, NC 28112

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Cincinnati, OH 45245

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Charleston, SC 29407

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Bellaire, TX 77401

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Dallas, TX 75230

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clincal Site

    Plano, TX 75024

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    San Antonio, TX 78215

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Sugar Land, TX 77478

    Site contact: CRO Call Center · participate@worldwide.com

  • Retension Clinical Site

    Vienna, VA 22182

    Site contact: CRO Call Center · participate@worldwide.com

Study contacts (from the official record)

  • Clinical Information · 7036242024 · clinicalinformation@retensionpharmaceuticals.com
All heart & blood pressure studies in Alabama →
A Study of Modified Release RTN-001 In Patients With Uncontrolled… (NCT07142356) | Bored Studies